Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ceruklin is a combination otic solution developed and marketed by Ordain Health Care (a division of Exeltis) for the treatment of impacted earwax (cerumen). The formulation contains four active components: paradichlorobenzene, which acts as a cerumenolytic to soften and disintegrate hardened wax; benzocaine, a local anesthetic that alleviates ear pain and discomfort; chlorobutanol, which provides preservative and mild local anesthetic effects; and turpentine oil, which serves as a solvent and lubricant to facilitate wax removal. It is primarily indicated for patients experiencing hearing loss, ear fullness, or pain due to excessive cerumen accumulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on paradichlorobenzene + benzocaine + chlorobutanol + turpentine oil.